Thrombocytopenia surgery

Revision as of 01:31, 20 December 2018 by Shyam Patel (talk | contribs)
Jump to navigation Jump to search

Thrombocytopenia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombocytopenia from other Diseases

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombocytopenia surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombocytopenia surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombocytopenia surgery

CDC on Thrombocytopenia surgery

Thrombocytopenia surgery in the news

Blogs on Thrombocytopenia surgery

Directions to Hospitals Treating Thrombocytopenia

Risk calculators and risk factors for Thrombocytopenia surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Overview

Surgery

Immune thrombocytopenia purpura (ITP)

Splenectomy is used as second-line treatment for ITP. The goal of splenectomy is to eliminate macrophage-induced phagocytosis of platelets in the spleen. The spleen is normally responsible for removing damaged platelets. Adverse effects include infection with encapsulated organisms (such as Neisseria, Haemophilus, and Streptococcus), inherent surgical risk, and high risk for thrombosis. Vaccinations must be completed 2 weeks prior to splenectomy to reduce the risk of post-splenectomy sepsis.

Congenital amegakaryocytic thrombocytopenia (CAMT)

Bone Marrow/Stem Cell transplant is the only measure that ultimately cures this genetic disease. Frequent platelet transfusions are required to keep the patient from bleeding to death until transplant is done.

References

Template:WS Template:WH